Phase 1 Every-3-Week Dosing of SCH 727965 in Patients With Advanced Cancer (Study P04630)
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
OHSU Knight Cancer Institute
University of Kansas Medical Center
Barbara Ann Karmanos Cancer Institute
Washington University School of Medicine